Enzyme Behavior Emulated By Synthetic Molecules For The First Time When chemists want to produce a lot of a substance -- such as a newly designed drug -- they often turn to catalysts, molecules that speed chemical reactions. Many jobs require highly specialized catalysts, and finding one in just the right shape to connect with certain molecules can be difficult. Natural catalysts, such as enzymes in the human body that help us digest food, get around this problem by shape-shifting to suit the task at hand.
Source: www.medicalnewstoday.comSCOLR Pharma, Inc. Advances Extended-Release Ibuprofen With Initiation Of Clinical Study SCOLR Pharma, Inc. (AMEX: DDD) announced the initiation of the third of three pivotal trials to evaluate the safety and efficacy of its formulation of 12-hour extended-release (ER) ibuprofen for the over-the-counter (OTC) market. The Company expects to complete the trial in late 2008. If approved, the Company believes its ibuprofen product would be the first and only OTC 12-hour, extended-release ibuprofen product on the market in the United States.
Source: www.medicalnewstoday.comCanadian Scientists Report On Pain Research At NIDCR's 60th Anniversary Symposium Nearly everyone has experienced the acute, short-lived pain that occurs after a mild injury, but recent surveys reveal that more than 20% of the population has a chronic pain condition (i.e., pain that has lasted for 3 months or more) and for which treatment is often not very effective (e.g., low back pain, fibromyalgia, migraine headaches). Acute and chronic pain conditions have huge socio-economic costs.
Source: www.medicalnewstoday.comCPPC Calls For A National Framework In England To Help Millions Suffering From Long Term Chronic Pain The Chronic Pain Policy Coalition (CPPC), established to promote better treatment for the 7.8 million who suffer from long-term chronic pain such as severe back pain or depression, is calling for a national chronic pain treatment framework for England in the light of the Darzi review into the future of the NHS.
Source: www.medicalnewstoday.comHighlights From EULAR 2008, The Annual European Congress Of Rheumatology Half of patients with early rheumatoid arthritis treated with the anti-tumour necrosis factor inhibitor (anti-TNF) infliximab plus methotrexate achieve remission, and up to one in five achieve drug-free remission, according to five-year follow-up results from the BeSt study. Patients treated initially with a combination of infliximab plus methotrexate achieved significantly better functional ability than those given other treatment regimens.
Source: www.medicalnewstoday.comCanadian Business Groups Applaud Bold, Competitive Vision Set Out By Competition Policy Review Panel A broad coalition of Canadian business groups welcomes the bold vision and ambitious scope of the final report of the Competition Policy Review Panel and calls on the federal government to secure the economic future of all Canadians by acting quickly on the report's recommendations.
Source: www.medicalnewstoday.comMS Drug Development Agreement Based On WEHI's Medicinal Chemistry Research conducted at The Walter and Eliza Hall Institute (WEHI) has contributed significantly to a major licensing agreement signed between Australian biotechnology company, Bionomics, (ASX:BNO) and Germany- based pharmaceutical company, Merck Serono. Under the Development and Licensing Agreement, Merck Serono will seek to develop new treatments for multiple sclerosis (MS) and other autoimmune conditions.
Source: www.medicalnewstoday.comTeva Receives First U.S. Approval For Generic Risperdal(R) Tablets; Commences Commercial Launch Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) announced that the U.S. Food and Drug Administration has granted final approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Janssen's antipsychotic agent Risperdal� (Risperidone) Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg. Shipment of these products has commenced.
Source: www.medicalnewstoday.com
# posted by Network @ 6:02 AM
